Arbutus Biopharma (ABUS) Enterprise Value (2010 - 2026)

Arbutus Biopharma has disclosed Enterprise Value across 17 years of filings, most recently posting -$86.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$86.0 million, up 15.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.0 million (up 15.69% YoY), and the FY2025 annual result was -$83.7 million, up 31.76% from the prior year.
• Enterprise Value came in at -$86.0 million for Q1 2026 at Arbutus Biopharma, down from -$83.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$83.7 million in Q4 2025 to a low of -$165.5 million in Q1 2022.
• The 5-year median for Enterprise Value is -$129.2 million (2024), against an average of -$126.0 million.
• Across the five-year window, Enterprise Value sank 91.63% in 2022 and surged 31.76% in 2025, its largest moves.
• Arbutus Biopharma's Enterprise Value stood at -$146.9 million in 2022, then gained by 14.23% to -$126.0 million in 2023, then climbed by 2.68% to -$122.6 million in 2024, then soared by 31.76% to -$83.7 million in 2025, then decreased by 2.78% to -$86.0 million in 2026.
• The last three Enterprise Value figures came in at -$86.0 million (Q1 2026), -$83.7 million (Q4 2025), and -$93.7 million (Q3 2025), per Business Quant data.